Post-transplantation cyclophosphamide vs tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation
Last Updated: Thursday, September 15, 2022
A single-center study analyzed the outcomes of 964 patients who received tacrolimus and methotrexate or post-transplantation cyclophosphamide (PTCy) for GvHD prophylaxis. It found that PTCy was associated with significantly improved relapse-free survival and lower risk of chronic GvHD.
Advertisement
News & Literature Highlights